Mianserin

CAS No:
24219-97-4 Category:
  • #LGM Pharma is a Mianserin CAS# 24219-97-4 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, delivery, purity, and more.
  • #Questions? Call our customer API support number 1-(800)-881-8210.
  • #LGM Pharma offers this active ingredient but not the finished dosage forms.

Product Details:

  • CAS No: 24219-97-4
  • AHFC code:
  • Synonyms: Mianserina [inn-spanish] Mianserine Mianserine [inn-french] Mianserinum [inn-latin] Mianseryna [polish]
  • ATC Code: N06AX03
  • Chemical Formula: C8H17NO5
  • Molecular Weight: 264.3648
  • Assay/Purity: Typically NLT 98%
  • DrugBank: DB06148
  • SMILES: CN1CCN2C(C1)C1=CC=CC=C1CC1=CC=CC=C21
  • InChl: UEQUQVLFIPOEMF-UHFFFAOYSA-N
  • PubChem: 4184
  • IUPAC: 5-methyl-2,5-diazatetracyclo[13.4.0.0^{2,7}.0^{8,13}]nonadeca-1(15),8(13),9,11,16,18-hexaene

Additional Details

Indication:
For the treatment of depression.
Pharmacodynamics:
Mianserin is a tetracyclic antidepressant that has antihistaminic and hypnosedative, but almost no anticholinergic, effect. It is a weak inhibitor of norepinephrine reuptake and strongly stimulates the release of norepinephrine. Interactions with serotonin receptors in the central nervous system have also been found. Its effect is usually noticeable after one to three weeks. Mianserin may cause drowsiness and hematological problems.
Mode of Action:
Mianserin's mechanism of therapeutic action is not well understood, although it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors.
Metabolism:
Hepatic.
Toxicity:
Oral rat LD50: 780mg/kg
General Reference:
Koyama E, Chiba K, Tani M, Ishizaki T: Identification of human cytochrome P450 isoforms involved in the stereoselective metabolism of mianserin enantiomers. J Pharmacol Exp Ther. 1996 Jul;278(1):21-30. Pubmed de Boer TH, Nefkens F, van Helvoirt A, van Delft AM: Differences in modulation of noradrenergic and serotonergic transmission by the alpha-2 adrenoceptor antagonists, mirtazapine, mianserin and idazoxan. J Pharmacol Exp Ther. 1996 May;277(2):852-60. Pubmed Kelder J, Funke C, De Boer T, Delbressine L, Leysen D, Nickolson V: A comparison of the physicochemical and biological properties of mirtazapine and mianserin. J Pharm Pharmacol. 1997 Apr;49(4):403-11. Pubmed
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Cost effective materials based on specific requirements
  • Small quantities for initial research and larger development quantities towards product commercialization

 

  • Technical packages, letters of access to filed DMFs
  • Complete assistance in any regulatory filings
  • Top quality GMP certified manufacturers
  • Have necessary regulatory credentials

 

Related YouTube Videos